XOMA Royalty Completes Acquisition of Generation Bio Co.

summarizeSummary

XOMA Royalty Corporation has finalized its acquisition of Generation Bio Co. through a tender offer and subsequent merger, making Generation Bio a wholly-owned subsidiary.

check_boxKey Events

• Acquisition Finalized

  XOMA Royalty completed the acquisition of Generation Bio Co. on February 9, 2026, following a tender offer that secured approximately 70% of Generation Bio's outstanding shares.

• Consideration Details

  Generation Bio shareholders received $4.2913 per share in cash, along with one non-tradeable contingent value right (CVR) per share, which provides for potential future payments.

• CVR Structure

  The CVRs are linked to future proceeds from Generation Bio's legacy assets, a Binney Lease arrangement, and a collaboration with Moderna, introducing contingent value.

• Financial Disclosure Pending

  Required financial statements and pro forma information related to the acquisition will be filed in an amendment within 71 days.

auto_awesomeAnalysis

This 8-K filing announces the completion of XOMA Royalty's acquisition of Generation Bio Co., a significant strategic move that was previously initiated with a merger agreement in December 2025 and a tender offer in January 2026. The acquisition was completed via a tender offer for $4.2913 cash per share plus one non-tradeable contingent value right (CVR) per share, followed by a short-form merger. The CVRs introduce a complex, contingent payment structure tied to future proceeds from Generation Bio's legacy assets, a Binney Lease arrangement, and a Moderna collaboration, adding a layer of uncertainty to the total consideration for former Generation Bio shareholders. The full financial impact of this acquisition will be detailed in an upcoming amendment to this 8-K.